Andy Guinigundo, RN, CNP, ANP-BC, FAPO’s Post

Why are structured, high-quality oncology knowledge bases important? Discuss ClinGen and OncoKB during the 1:15 PM plenary session with Dr. Debyani Chakravarty and Dr. Heidi Rehm. #AMPath23

NEW SOCRA Blog: Take a look inside the 2024 SOCRA Oncology Clinical Trials Conference. Program Chairs Tammy Neseth & Susanna Sellmann discuss the upcoming conference in San Antonio, TX March 13-15, 2024. Read the Blog Here: https://smpl.is/8gbyv Learn More About the Oncology Conference: https://smpl.is/8gbyw #socra #clinicalresearcheducation #oncologyclinicaltrials

Hello Boston. Translational Drug Development (TD2) is at Clinical Trials in Oncology East Coast. Visit our booth and learn how TD2 can help advance your cancer therapeutic program (from bench to bedside). While I won't be there (why did I hear a huge sigh of relief 😉), my colleague Parris Johnson is the man you want to speak with anyway. Don't worry, I'll be back for Tumor Models Boston in a couple weeks. #clinicaltrials #cancertherapeutic #oncology #tumormodelsboston #tumormodels #clinicaldevelopment #preclinical

Countdown to ASCO 2024! We're eager to share insights and discuss how we can support your clinical trial strategies from June 1-3. Ready to transform oncology clinical trials? Let's collaborate on your next project. #CaidyaOncology #TransformOncology #ASCO2024

Review what was discussed at the 2023 Precision Oncology Forum in regards to best practices & challenges involved in building an effective precision oncology program, by Jazieh et al. https://lnkd.in/gMk-HKtf #precisiononcology #JIPO

Announced today! Canopy’s latest ePRO study has been selected for poster presentation at this year’s American Society of Clinical Oncology (ASCO) Meeting. The real-world study, led by Dr. Michael Kolodziej, demonstrates improved high-risk symptom detection and comparable outcomes with ePRO compared to phone triage. This builds on Canopy’s existing research on the clinical impact of ePROs, which demonstrates: • A 22% reduction in ER visits and hospitalizations [ASCO 2022] • Up to a 45% increase in treatment persistence at 3 months [ASCO 2022] • 88% patient engagement at 6 months [JCO, 2022] Read our official press release to learn more: https://lnkd.in/e5AxpTpC Attending ASCO? Schedule time with our team: https://lnkd.in/erNjbPbg

Is your site considering phase 1 oncology trials? SCRS has a guide that outlines several major considerations a site should explore when considering these types of trials. Access it here ⇢ https://lnkd.in/gBqrX2TX

Is your site considering phase 1 oncology trials? SCRS has a guide that outlines several major considerations a site should explore when considering these types of trials. Access it here ⇢ https://lnkd.in/gBqrX2TX

Valuable information #oncology #clinicaltrial professionals.

Are you aware of the recent implementation of the EU Clinical Trials Regulation No 536/2014 and how that will affect your oncology program? Find out in my team members’ blog: Navigating the Complex Regulatory CRO Landscape for Oncology Trials in the EU https://bit.ly/3WEcxga